NASDAQ:CDXS Codexis (CDXS) Stock Forecast, Price & News $1.70 +0.15 (+9.68%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$1.55▼$1.7150-Day Range$1.50▼$3.7552-Week Range$1.45▼$6.98Volume862,466 shsAverage Volume878,278 shsMarket Capitalization$118.66 millionP/E RatioN/ADividend YieldN/APrice Target$7.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Codexis MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside362.1% Upside$7.83 Price TargetShort InterestHealthy3.44% of Shares Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.84Based on 4 Articles This WeekInsider TradingAcquiring Shares$55,403 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.96) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector256th out of 975 stocksIndustrial Organic Chemicals Industry5th out of 19 stocks 3.3 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.83, Codexis has a forecasted upside of 362.1% from its current price of $1.70.Amount of Analyst CoverageCodexis has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.44% of the outstanding shares of Codexis have been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Codexis has recently increased by 1.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 3.2 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $55,403.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.30% of the stock of Codexis is held by insiders.Percentage Held by Institutions87.94% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.96) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Codexis (NASDAQ:CDXS) StockCodexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Read More CDXS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXS Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Raised to "Hold" at StockNews.comSeptember 20, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Lowered to Sell at StockNews.comSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 18, 2023 | finance.yahoo.comCodexis CEO Stephen Dilly Named as Finalist of 2023 Bloom Burton AwardSeptember 13, 2023 | marketwatch.comCodexis Stock Climbs After Executives Buy Up SharesSeptember 13, 2023 | msn.comCodexis shares up after CFO buys 11,650 sharesSeptember 13, 2023 | finance.yahoo.comInsider Buying: Kevin Norrett Acquires 9,000 Shares of Codexis Inc (CDXS)September 12, 2023 | finance.yahoo.comCodexis to Participate in Cantor Global Healthcare ConferenceSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)Unlock the treasure on Mount Olympus with this little-known mining stock.Investor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsSeptember 8, 2023 | bizjournals.comPeninsula biotech grabs more space as it plans to take 2nd pneumonia vaccine into clinicSeptember 8, 2023 | msn.comCodexis announces a San Carlos facility lease that could potentially save $30MSeptember 8, 2023 | finance.yahoo.comCodexis Announces Agreement for Assignment and Assumption of San Carlos Facility LeaseSeptember 2, 2023 | nasdaq.comBenchmark Reiterates Codexis (CDXS) Buy RecommendationAugust 14, 2023 | msn.comStifel Maintains Codexis (CDXS) Buy RecommendationAugust 8, 2023 | finance.yahoo.comBlackRock Inc. Acquires Significant Stake in Codexis Inc.August 5, 2023 | fool.comCodexis (NASDAQ: CDXS)August 4, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Technology Companies: Codexis (CDXS), Clearfield (CLFD) and Climb Global Solutions (CLMB)August 3, 2023 | finance.yahoo.comCodexis Reports Second Quarter 2023 Financial ResultsJuly 31, 2023 | finance.yahoo.comCodexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel TherapeuticsJuly 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Technology Companies: Infosys (INFY) and Codexis (CDXS)July 22, 2023 | msn.comStephens & Co. Reiterates Codexis (CDXS) Overweight RecommendationJuly 21, 2023 | benzinga.comCodexis' Strategic Focus: Discontinues Biotherapeutics Development, Lays Off 25% Of Employees, Cash Runway Into Mid-2026July 21, 2023 | seekingalpha.comCodexis streamlining operations, reducing headcountJuly 20, 2023 | bizjournals.comCodexis pulls back from biotherapeutics as it cuts staff by 25%July 20, 2023 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Codexis (CDXS)July 11, 2023 | finance.yahoo.com2 ‘Strong Buy’ Penny Stocks With Massive 300% Upside Potential — Or MoreJuly 10, 2023 | finance.yahoo.comCodexis (NASDAQ:CDXS) shareholders have endured a 82% loss from investing in the stock five years agoSee More Headlines Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Company Calendar Last Earnings8/03/2023Today9/28/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Industrial organic chemicals Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees248Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.83 High Stock Price Forecast$14.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+376.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,590,000.00 Net Margins-57.22% Pretax Margin-57.04% Return on Equity-41.33% Return on Assets-24.92% Debt Debt-to-Equity RatioN/A Current Ratio3.36 Quick Ratio3.30 Sales & Book Value Annual Sales$138.59 million Price / Sales0.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book0.75Miscellaneous Outstanding Shares69,800,000Free Float65,406,000Market Cap$114.82 million OptionableOptionable Beta1.79 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Stephen George Dilly MBBS (Age 63)Ph.D., Pres, CEO & Director Comp: $753.61kMr. Kevin Norrett M.B.A. (Age 50)M.S., Chief Operating Officer Comp: $507.28kMs. Margaret Fitzgerald J.D. (Age 52)Chief Legal and Compliance Officer, Gen. Counsel & Sec. Comp: $300.03kMr. Sriram Ryali M.B.A. (Age 41)Chief Financial Officer Carrie McKimDirector of Investor RelationsMs. Karen Frechou-ArmijoSr. VP & Head of HRDr. Stefan Lutz Ph.D.Sr. VP of ResearchMr. Robert Sato M.B.A.Ph.D., Sr. VP of Pharmaceutical Devel., Quality & RegulatoryMore ExecutivesKey CompetitorsCue BiopharmaNASDAQ:CUEVaccitechNASDAQ:VACCApyx MedicalNASDAQ:APYXReviva PharmaceuticalsNASDAQ:RVPHOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsBarclays PLCSold 17,691 shares on 9/21/2023Ownership: 0.061%Kevin NorrettBought 9,000 shares on 9/11/2023Total: $15,480.00 ($1.72/share)Sriram RyaliBought 11,650 shares on 9/8/2023Total: $19,805.00 ($1.70/share)Margaret Nell FitzgeraldBought 11,834 shares on 9/8/2023Total: $20,117.80 ($1.70/share)California State Teachers Retirement SystemSold 52,417 shares on 8/21/2023Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions CDXS Stock - Frequently Asked Questions Should I buy or sell Codexis stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks. What is Codexis' stock price forecast for 2023? 6 Wall Street analysts have issued 1 year target prices for Codexis' shares. Their CDXS share price forecasts range from $4.00 to $14.00. On average, they anticipate the company's share price to reach $7.83 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts. How have CDXS shares performed in 2023? Codexis' stock was trading at $4.66 at the start of the year. Since then, CDXS stock has decreased by 64.7% and is now trading at $1.6450. View the best growth stocks for 2023 here. When is Codexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our CDXS earnings forecast. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The biotechnology company earned $21.32 million during the quarter, compared to analyst estimates of $19.83 million. Codexis had a negative net margin of 57.22% and a negative trailing twelve-month return on equity of 41.33%. The business's revenue was down 44.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share. What ETFs hold Codexis' stock? ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG).Inspire Small/Mid Cap ETF (ISMD). What guidance has Codexis issued on next quarter's earnings? Codexis updated its earnings guidance on Monday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.00 million-$22.00 million, compared to the consensus revenue estimate of $18.09 million. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). What is Codexis' stock symbol? Codexis trades on the NASDAQ under the ticker symbol "CDXS." Who are Codexis' major shareholders? Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.46%), Baillie Gifford & Co. (9.20%), ARK Investment Management LLC (6.18%), Nuveen Asset Management LLC (2.58%), Geode Capital Management LLC (1.92%) and State Street Corp (1.82%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Codexis' stock price today? One share of CDXS stock can currently be purchased for approximately $1.65. How much money does Codexis make? Codexis (NASDAQ:CDXS) has a market capitalization of $114.82 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. How many employees does Codexis have? The company employs 248 workers across the globe. How can I contact Codexis? Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102. This page (NASDAQ:CDXS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.